At last. A safe, druggable TLR-3 agonist.
Glysantis has developed a monodisperse nanoparticle which safely delivers immune-activating compounds to tumors, reversing immunosuppression and activating anti-tumor immunity… “making cold tumors hot”.
Many lethal cancers suppress the immune system or even evade immune detection.
These tumors remain effectively invisible to the body’s immune system, allowing rapid disease progression despite treatment.
We need a better way to safely recruit the immune system in the battle against immunosuppressed cancers.
Decloaking cancer
GLY100™ exposes immunosuppressed tumors to immune system attack.
Our initial focus is improving outcomes for ovarian cancer patients. Our long-term vision is to tackle other difficult-to-treat tumors by enhancing existing therapies.
Our breakthrough
Our monodisperse nanoparticle revolutionizes the delivery of immune-activating agents to tumors.
- Strong immune response
- Non-toxic
- Stable in blood
From insight to platform
Glysantis is led by experienced executives with a track record of building and scaling science‑based organizations and is supported by key academic and knowledge partnerships.
What's next?
We are rapidly moving towards clinical trials and welcome outreach from scientific collaborators, strategic partners, and interested investors aligned with our mission.
- Scientific collaboration
- Strategic partnerships
- Investor inquiries